Supported by the Mark Hughes Foundation
Targeted treatments, new management strategies and clinical trials - an international perspective.
The Hunter Medical Research Institute and the Mark Hughes Foundation are proud to welcome international brain cancer expert Dr Susan Chang and Research Fellow Dr Mike Fay to talk on their current research.
Dr Mike Fay is a nationally renowned radiation oncologist who was the inaugural recipient of the HMRI Mid-Career research Fellowship in Brain Cancer supported by the Mark Hughes Foundation. Mike’s research focusses on specially targeted therapies based on targeted diagnostic tests.
Dr Susan Chang is the Director of the UCSF Division of Neuro-Oncology and is an internationally recognized leader in the field of neurological malignancies. Her research expertise is in clinical trial design and the development of novel therapies and imaging biomarkers for brain tumors. Dr. Chang is the principal investigator and co-investigator on more than 20 active clinical trials that evaluate the wide spectrum of therapeutic interventions, spanning chemotherapy, targeted agents, immunotherapy, and convection-enhanced delivery of novel agents. Dr. Chang also has a strong interest in quality-of-life issues faced by patients with brain tumors and their families.
Register your Attendance
Join us on Saturday, 13 October, and hear from two world leading researchers who will be happy to answer your questions about current and future brain cancer treatments. At this seminar you will not only hear about the exciting research being undertaken in the Hunter but be given a firsthand account of research and treatments from across the globe.
This event is being recorded and will be live streamed on Facebook. The recorded material may also be edited and used in other forms including social media, radio, television, newspaper, magazine, internet or other means.
By attending and participating in this event you authorise your likeness and voice, and any activity undertaken in relation to this event to be used by Hunter Medical Research Institute, University of Newcastle and Hunter New England Health and acknowledge that you assign all rights, title and interest including copyright to HMRI in perpetuity.